Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy.
The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen. Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed. It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.
The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy.
The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen. Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed. It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.
The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.